The Technical Analyst
SPDR Select Sector Fund - [XLV]
Exchange: NYSE
SPDR Select Sector Fund - Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.46% $142.74
America/New_York / 9 mai 2024 @ 10:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 28 179 mill |
| EPS: | 5.90 |
| P/E: | 24.18 |
| Earnings Date: | N/A |
| SharesOutstanding: | 197.42 mill |
| Avg Daily Volume: | 8.56 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.01x |
| Company: PE 24.18 | sector: PE 23.85 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.79x |
| Company: PE 24.18 | industry: PE 13.52 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 141.15 - 144.16 ( +/- 1.05%) |
| ATR Model: 14 days |
Forecast:
12:08 - $142.81
Live Trading Signals (every 1 min)
Forecast
1: 10:38 - $142.76
Forecast 2: 11:28 - $142.81
Forecast 3: 12:08 - $142.81
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $142.74 (0.46% ) |
| Volume | 1.568 mill |
| Avg. Vol. | 8.56 mill |
| % of Avg. Vol | 18.31 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XLV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
XLV
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Latest News
2024-05-06 14:30:17 - InvestorPlace
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotechnology sector is renowned for its potential to deliver groundbreaking medical treatments while offering investors the possibility of significant returns. However, investing in these companies requires a nuanced understanding of their pipelines, regulatory landscapes and market dynamics.
2024-05-06 14:01:04 - Zacks Investment Research
4 Sector ETFs & Stocks Likely to Benefit Despite Soft Jobs Data
The U.S. economy added 175, 000 jobs in April, well below Wall Street expectations of 240, 000.
2024-04-29 06:00:00 - Seeking Alpha
XLV: Pivotal Week Of Earnings For Healthcare Stocks
A trio of top 10 holdings from this S&P 500 healthcare sector ETF report this week (LLY, the largest holding, PFE and AMGN). Despite being loaded with quality businesses, this sector is not showing signs I look for to produce high long-term returns from here, and I think a full washout is needed first. I rate XLV a Hold because it is bent but not broken, but I am very underweight healthcare for now.
2024-04-24 13:06:03 - Zacks Investment Research
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
2024-04-24 09:01:06 - Zacks Investment Research
Beyond "Big Six:" Why Choose Non-Cyclical Sector ETFs?
UBS pointed out that rapid earnings growth recorded by the big six tech giants over the past year is now ebbing. Hence, this could be the time to bet on non-cyclical sectors.
2024-04-20 06:15:00 - InvestorPlace
3 Biotech Stocks Set to Double by 2028
Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies possesses the potential to deliver substantial returns in the coming years.
2024-04-17 12:11:04 - Zacks Investment Research
UnitedHealth Rises on Q1 Earnings Beat: ETFs to Gain
UnitedHealth Group (UNH) breezed past the Zacks Consensus Estimate on both earnings and revenues.
2024-04-17 11:00:19 - Zacks Investment Research
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
2024-04-11 15:11:03 - Zacks Investment Research
4 Sector ETFs & Stocks to Benefit From Hot Inflation
U.S. inflation jumped in March, surpassing expectations primarily due to higher petrol and shelter costs, dashing hopes of a June interest rate cut by the Fed.
2024-04-10 09:27:00 - Market Watch
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.